Back to List View Graph View

MYC proto-oncogene (MYC)

MYC (c-Myc) is a nuclear phosphoprotein that acts as a sequence-specific transcription factor and ranks among the most frequently deregulated oncoproteins in human cancer.

Where the papers sit

21 papers from the last 6 months study MYC proto-oncogene (MYC) directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 2 observational · 2 human data · 11 preclinical · 6 unclassified

Themes one subject

Those 21 are all about one subject.

  • MYC-Driven Disease Biology

    MYC expression, amplification and signaling recur across diverse cancer and disease contexts. Cancer studies link MYC to neuroendocrine neoplasms, lymphoma, myeloma, leukemia, colorectal cancer and solid-tumour progression. Therapeutic work is moving toward direct MYC reduction through antibody delivery, RNA degraders and nano-PROTACs, alongside pathway inhibition and immunotherapy. Other studies connect MYC with tissue injury and stress-related disease, leaving the overall evidence broad rather than convergent on one treatment strategy.

    21 papers

Papers

The 21 papers from the last 6 months that study MYC proto-oncogene (MYC) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

MYC-Driven Disease Biology (21)
  1. Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms. Endocrine pathology · 12 Sept 2026 PMID 42730951
  2. Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways. Apoptosis : an international journal on programmed cell death · 23 Aug 2026 PMID 42634031
  3. Intracellular Delivery of Antibody-Based Therapeutics for Targeted Oncogenic c-Myc Degradation in Mammalian Cells and Mice. Angewandte Chemie (International ed. in English) · 20 Aug 2026 PMID 42622261
  4. Sequential Disruption of Tumor Camouflage and Metabolic Coercion by Cascade-Acting Nano-Proteolysis Targeting Chimera Engines to Reprogram the Immune Ecosystem. ACS nano · 11 Aug 2026 PMID 42579417
  5. A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models. Blood · 29 Jul 2026 PMID 42526890
  6. Betulinic Acid Promotes Motor Function Recovery After Spinal Cord Injury by Inhibiting Apoptosis Through Myc/NF-κB Signaling Pathway. Neurochemical research · 20 Jul 2026 PMID 42477269
  7. Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
  8. PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. Materials today. Bio · 12 Jul 2026 PMID 42436803
  9. Psychological Stress Associated Bile Acid Reprogramming Promotes Hepatocellular Carcinoma Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 11 Jul 2026 PMID 42435771
  10. Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression. Hematology (Amsterdam, Netherlands) · 29 Jun 2026 PMID 42372253
  11. Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
  12. The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research · 24 Jun 2026 PMID 42340371
  13. Large-scale and high-resolution mass spectrometry-based proteomics defines molecular subtypes of nasopharyngeal carcinoma for therapeutic targeting. Signal transduction and targeted therapy · 22 Jun 2026 PMID 42331772
  14. A four-gene signature for diagnosis of acute kidney injury following kidney transplantation. Renal failure · 18 Jun 2026 PMID 42315974
  15. Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer cell · 18 Jun 2026 PMID 42314664
  16. MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy. Functional & integrative genomics · 17 Jun 2026 PMID 42307804
  17. Dual Functional Potential of Poly(ADP-Ribose) Polymerase Inhibitor VIII: A Promising G-Quadruplex Stabilizer Targeting the Promoter of Oncogenes. Chemphyschem : a European journal of chemical physics and physical chemistry · 12 Jun 2026 PMID 42281329
  18. The NAT10/c-Myc positive feedback loop orchestrates tRNA ac4C modification and OTUB1-mediated protein stabilization to drive anaplastic thyroid carcinoma progression. Cellular & molecular biology letters · 12 Jun 2026 PMID 42277649
  19. Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
  20. Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell · 4 Jun 2026 PMID 42242231
  21. Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma. Anticancer research · 27 May 2026 PMID 42203345

By study type

Observational studies and case reports (2)
  1. Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms. Endocrine pathology · 12 Sept 2026 PMID 42730951
  2. Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
Human data, design not indexed (2)
  1. The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research · 24 Jun 2026 PMID 42340371
  2. Dual Functional Potential of Poly(ADP-Ribose) Polymerase Inhibitor VIII: A Promising G-Quadruplex Stabilizer Targeting the Promoter of Oncogenes. Chemphyschem : a European journal of chemical physics and physical chemistry · 12 Jun 2026 PMID 42281329
Preclinical: animal, cell and lab studies (11)
  1. Alantolactone inhibits T-cell lymphoma progression by suppressing CD47 expression via the PI3K/AKT and ERK signaling pathways. Apoptosis : an international journal on programmed cell death · 23 Aug 2026 PMID 42634031
  2. Intracellular Delivery of Antibody-Based Therapeutics for Targeted Oncogenic c-Myc Degradation in Mammalian Cells and Mice. Angewandte Chemie (International ed. in English) · 20 Aug 2026 PMID 42622261
  3. Sequential Disruption of Tumor Camouflage and Metabolic Coercion by Cascade-Acting Nano-Proteolysis Targeting Chimera Engines to Reprogram the Immune Ecosystem. ACS nano · 11 Aug 2026 PMID 42579417
  4. Betulinic Acid Promotes Motor Function Recovery After Spinal Cord Injury by Inhibiting Apoptosis Through Myc/NF-κB Signaling Pathway. Neurochemical research · 20 Jul 2026 PMID 42477269
  5. Investigating the mechanisms of malignant progression in colorectal cancer using weighted gene co-expression network analysis and machine learning. Journal of molecular histology · 18 Jul 2026 PMID 42470494
  6. Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression. Hematology (Amsterdam, Netherlands) · 29 Jun 2026 PMID 42372253
  7. Novel patient-derived tongue squamous cell carcinoma cell lines from non-smokers: 3D and in vivo models for drug response studies. Medical oncology (Northwood, London, England) · 29 Jun 2026 PMID 42371352
  8. A four-gene signature for diagnosis of acute kidney injury following kidney transplantation. Renal failure · 18 Jun 2026 PMID 42315974
  9. Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer cell · 18 Jun 2026 PMID 42314664
  10. MO-IPS suppresses acute myeloid leukemia through metabolic reprogramming and synergizes with anti-PD-1 immunotherapy. Functional & integrative genomics · 17 Jun 2026 PMID 42307804
  11. Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma. Anticancer research · 27 May 2026 PMID 42203345
Unclassified: not yet indexed with MeSH (6)
  1. A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models. Blood · 29 Jul 2026 PMID 42526890
  2. PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy. Materials today. Bio · 12 Jul 2026 PMID 42436803
  3. Psychological Stress Associated Bile Acid Reprogramming Promotes Hepatocellular Carcinoma Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 11 Jul 2026 PMID 42435771
  4. Large-scale and high-resolution mass spectrometry-based proteomics defines molecular subtypes of nasopharyngeal carcinoma for therapeutic targeting. Signal transduction and targeted therapy · 22 Jun 2026 PMID 42331772
  5. The NAT10/c-Myc positive feedback loop orchestrates tRNA ac4C modification and OTUB1-mediated protein stabilization to drive anaplastic thyroid carcinoma progression. Cellular & molecular biology letters · 12 Jun 2026 PMID 42277649
  6. Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell · 4 Jun 2026 PMID 42242231